{"name":"Retinal Consultants of Arizona","slug":"retinal-consultants-of-arizona","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Lucentis every 4 weeks","genericName":"Lucentis every 4 weeks","slug":"lucentis-every-4-weeks","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"},{"name":"Lucentis (Treat and extend)","genericName":"Lucentis (Treat and extend)","slug":"lucentis-treat-and-extend","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"},{"name":"Lucentis every 12 weeks","genericName":"Lucentis every 12 weeks","slug":"lucentis-every-12-weeks","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"}]}],"pipeline":[{"name":"Lucentis every 4 weeks","genericName":"Lucentis every 4 weeks","slug":"lucentis-every-4-weeks","phase":"marketed","mechanism":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy"],"catalyst":""},{"name":"Lucentis (Treat and extend)","genericName":"Lucentis (Treat and extend)","slug":"lucentis-treat-and-extend","phase":"marketed","mechanism":"Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy"],"catalyst":""},{"name":"Lucentis every 12 weeks","genericName":"Lucentis every 12 weeks","slug":"lucentis-every-12-weeks","phase":"marketed","mechanism":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPWWxJUDJLUDBoQ25PWkVpc0plTGkzeGpHSlM4RFdTd1RaWlgxOVVEaENHT2I0REVVUzVmNXFUeXRFYXpLRGRzTk5TZC1sd2ZlaVhzZEhDV0lyYW9aWDJUeXY2MU9RS2ptVW5qRVJJdFZkeXdRbFhEVGZ2dXhuZVdINUdvM1JnT0g3eWVsNTZXV01hRG0xM05EdHBB?oc=5","date":"2024-11-06","type":"deal","source":"pehub.com","summary":"Webster Equity Partners to sell Retina Consultants of America for $4.6bn - pehub.com","headline":"Webster Equity Partners to sell Retina Consultants of America for $4.6bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPX3h5OGRDYmFsV0g0WmluaWFMWnBoMVFoTHpYNzZwaHFVWG1Wa2hTS0dtNUFNdHRTYUhqb0tiOHRHVnFzQmVkZENVNHJaWDJCbldVOG1hWk5sNHpKbERLYml4LVFFdUQtSHZXdDJYa0R4VU03SjF0eEdXX09scGh6OVhnc0V5SnE1QVhrdVZfUHJBSDhJc1lfSVdPWFdIVE1CVF9PQTl5cTM1S09DT25kSkxPbExQMlh2?oc=5","date":"2024-04-29","type":"trial","source":"Ocugen, Inc.","summary":"Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 | Ocugen, Inc. - Ocugen, Inc.","headline":"Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 20","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE52aFN6OWhXaDVkcFViUGNqZzFKYnV4cjZGRzNfNjNLaXQ2RUFjTlRpOHRXSU5wNjRMdjdBeEpaUTE5YXk4MllOWE1aRDVldldfdHNLY2RXbHZwOG43Q3RV?oc=5","date":"2023-05-12","type":"trial","source":"nature.com","summary":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results - nature.com","headline":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPeEdvdF90cFcxZUFzVGlCR0YxcW1LUzFYMHpQRjM3RGg4Q0lwaW1oTDVTUmV0OE1xRHN6ZXJtb0o5WS1ZNFY2N3NWWjRyakVKdi1kRk9oVDVQLUlPTElCdUc4OHdoQlRUSjhCNUplZ3ZNZURyN3h0MmxlU20wYWV3TU15UDQwa1N0cEljR2h2MUprZzZhUjRRZ1JsZUtDYldUMGFUOUhUbTUySmpnN0MzWERR?oc=5","date":"2022-08-09","type":"pipeline","source":"BioSpace","summary":"Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases - BioSpace","headline":"Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNVVc4U0dyRnVWYXJlb0c0TWtQUE5SeXRkbjJfT3ZOTjRBdV9SaXo5T211X25TSF9UbzRKS0ZUUlNVVGZCSkF0dFoyUEJwRDR5RnNQYkJ1Q3BFckRBUFBGR0Y1b08tWmhCb2hCTXpGcXNmWjFXeWRQMzR6cGNlWmIzVEczYUVHaDdCZWRjVjVVb0c1YjlBSWF4SWhkRU9oRmVmQnZXU0UtSVE1NU1pMGFGZnhmbzRTcmNqendSdnNqbjVvN1lDY1JMVkVFMkNyVHlY?oc=5","date":"2015-04-21","type":"regulatory","source":"BioSpace","summary":"Alimera Sciences Release: ILUVIEN Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S. - BioSpace","headline":"Alimera Sciences Release: ILUVIEN Is Now Widely Available To Diabetic Macular Edema Patients Throughout The U.S.","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}